ClinicalTrials.gg
Status unknownNCT04476394Updated Jul 20, 2020

Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-20 mg/100 μCi Anaprazole Sodium Enteric-coated Capsule in Healthy Adult Male Subjects

A Phase 1 interventional study of [14C]-Anaprazole Sodium enteric-coated capsule in Healthy Male Volunteers, sponsored by Sihuan Pharmaceutical Holdings Group Ltd.. Status unknown. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-20.

Sponsored by Sihuan Pharmaceutical Holdings Group Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single oral dose of [14C]-20 mg/100 μCi Anaprazole Sodium enteric-coated capsule in healthy adult male subjects. Whole blood, plasma samples will be collected at hour 0 pre-dose and 1,2,3,4,5,6,8,12,24,48,72,96,120,144,168 hours post-dose (tentative, adjusted according to plasma drug concentration); urine samples will be collected at hour 24 pre-dose and 0-4,4-8,8-12,12-24,24-48,48-72,72-96,96-120,120-144,144-168,168-192,192-216,216-240 hours post-dose (tentative, adjusted according to sample recovery rate) ; fecal samples will be collected at hour 24 pre-dose and 0-24,24-48,48-72,72-96,96-120,120-144,144-168,168-192,192-216,216-240 hours post-dose (tentative, adjusted according to sample recovery rate) following the start of administration to measure total radioactivity and plasma drug concentrations.

02

Conditions studied

  • Healthy Male Volunteers
03

In context

Lead sponsor

Sihuan Pharmaceutical Holdings Group Ltd. is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.The subject is a Chinese adult male, aged 18 to 45 years, inclusive.
  • 2.The subject weighed at least 50.0 kg and had a (BMI) between 19.0 kg/m\^2 and 26.0 kg/m\^2, inclusive.
    1. Participants with evaluations of vital signs, physicial examination results,clinical laboratory and testing outside the reference range that are deemed not at investigator discretion at screening.
  • 4.The subject with agrees that the subject and his sexual partner use adequate from signing of throughout the duration of the study and for 6 months after study completion.
  • 5.The subject is capable of understanding and complying with protocol requirements, and signed and dated a written informed consent form voluntarily

Exclusion criteria

Exclusion Criteria:

  • 1.Has clinical significant drug allergy or allergic disease history(Such as asthma, urticaria, eczema dermatitis, etc), or has or allergy to investigatory drugs or related supplements;
  • 2.Has clinical significant abnormal history or family history of long syndrome(Grandparents, parents and siblings)
  • 3.Any disease or medical history that may significantly affect the absorption, distribution, metabolism, and excretion of drugs, or any condition that may pose a hazard to the subject. Such as:

    • Inflammatory bowel disease, gastric ulcer, duodenal ulcer, gastrointestinal / rectal bleeding, persistent nausea, or other gastrointestinal abnormalities;
    • Has suffered from gastrointestinal diseases or complications that may affect the absorption of drugs (ie: malabsorption, gastroesophageal reflux, peptic ulcer, erosive esophagitis, frequent heartburn) within 6 months before screening or had history of gastrointestinal surgery (for example: gastrectomy, gastrointestinal anastomosis, intestinal resection, gastric bypass, gastric segmentation or gastric banding, cholecystectomy, except for appendicitis surgery and proctectomy);
    • Evidence of liver disease or clinically impaired liver function at the time of screening (eg , ALT or total > 1.5 times );
    • A history or evidence of nephropathy or renal insufficiency at the time of screening, showing clinically significant abnormality of creatinine or abnormal urine composition (such as proteinuria, creatinine> 176.8 umol / L, etc.)
    • Has difficulty swallowing oral preparations.
  • 4.Thyroid stimulating hormone (TSH)> ULN; or serum free triiodothyronine (FT3)> ULN; or serum free thyroxine (FT4)> ULN at the time of screening;
    1. Frequent smokers and alcoholics within 3 months before screening (smoke more than 5 cigarettes / day, drink more than 21 units of alcohol per week, 1 unit = 360 mL beer or 45 mL liquor or 150 mL wine), or can't stop using any tobacco products, and alcohol intake during the study period ; or those who have a positive alcohol breath test before enrollment;
    1. Has received any compound (including post-marketing investigational drugs) or participated in clinical trials of any drugs /devices within 3 months before screening;
    1. A history of drug abuse within 12 months before screening or a positive urine test result at screening;
    1. Has used any prescription drugs, non-prescription drugs (including chemical drugs, vitamin drugs, Chinese herbal medicines, etc.) within 4 weeks before administration of investigational drugs;
    1. Has taken foods that affect (such as grapefruit or beverages containing grapefruit) within 2 weeks before administration of investigational drugs;
    1. antibody, surface antigen, antibody, and Treponema pallidum specific antibody test results were positive at screening;
    1. Has difficulty in venous blood collection or halo acupuncture;
  • 12.Blood donation / blood loss ≥200 mL within 1 month, or ≥400 mL within 3 months before screening; or has blood donation plan during the period of medication of investigational drugs and within 3 months after drug withdrawal;
    1. Has special dietary requirements and cannot follow the unified dietary arrangements;
    1. Has particpated in another clinical study with radioactive labeling within 1 year before administration.
    1. Has significant radiation exposure (Radiation exposure from chest X-ray, CT scan or barium meal examination more than once, or be engaged in radiation related occupations) within 1 year before administration.
    1. Any conditions in which considered by investigator not be appropriate to participate in this trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    1

    Administered orally once

    Drug: [14C]-Anaprazole Sodium enteric-coated capsule

Interventions

  • Drug[14C]-Anaprazole Sodium enteric-coated capsule

    \[14C\]-Anaprazole Sodium enteric-coated capsule

06

What researchers measure

Primary outcomes

  1. Cmax of Anaprazole according to total radioactivity concentration equivalents in whole blood and plasma

    Cmax is the peak plasma concentration

    Time frame: Hour 0 pre-dose and 1,2,3,4,5,6,8,12,24,48,72,96,120,144,168 hours post-dose (tentative, adjusted according to plasma drug concentration)

  2. Tmax of Anaprazole according to total radioactivity concentration equivalents in whole blood and plasma

    Tmax is the time to maximum plasma concentration

    Time frame: Hour 0 pre-dose and 1,2,3,4,5,6,8,12,24,48,72,96,120,144,168 hours post-dose (tentative, adjusted according to plasma drug concentration)

  3. AUC of Anaprazole according to total radioactivity concentration equivalents in whole blood and plasma

    AUC is area under the plasma concentration-time curve

    Time frame: Hour 0 pre-dose and 1,2,3,4,5,6,8,12,24,48,72,96,120,144,168 hours post-dose (tentative, adjusted according to plasma drug concentration)

  4. Cumulative excretion and cumulative excretion rate in urine

    Sum of the percent of the total radioactivity recovered in urine relative to the administered radioactivity dose

    Time frame: Hour 24 pre-dose and 0-4,4-8,8-12,12-24,24-48,48-72,72-96,96-120,120-144,144-168,168-192,192-216,216-240 hours post-dose (tentative, adjusted according to sample recovery rate)

  5. Cumulative excretion and cumulative excretion rate in feces

    Sum of the percent of the total radioactivity recovered in feces relative to the administered radioactivity dose

    Time frame: Hour 24 pre-dose and 0-24,24-48,48-72,72-96,96-120,120-144,144-168,168-192,192-216,216-240 hours post-dose (tentative, adjusted according to sample recovery rate)

  6. Radioactivity spectrum indentification of metabolites in plasma

    plasma concentration of metabolites

    Time frame: Hour 0 pre-dose and 1,2,3,4,5,6,8,12,24,48,72,96,120,144,168 hours post-dose (tentative, adjusted according to plasma drug concentration)

  7. Radioactivity spectrum indentification of metabolites in urine

    Concentration of metabolites in urine

    Time frame: Hour 24 pre-dose and 0-4,4-8,8-12,12-24,24-48,48-72,72-96,96-120,120-144,144-168,168-192,192-216,216-240 hours post-dose (tentative, adjusted according to sample recovery rate)

  8. Concentration of metabolites in feces

    Sum of the percent of the total radioactivity recovered in feces relative to the administered radioactivity dose

    Time frame: Hour 24 pre-dose and 0-24,24-48,48-72,72-96,96-120,120-144,144-168,168-192,192-216,216-240 hours post-dose (tentative, adjusted according to sample recovery rate)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2020; primary completion for Sep 2020, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2020
First posted
Jul 20, 2020
StartEst.
Aug 3, 2020
Primary completionEst.
Sep 30, 2020
CompletionEst.
Sep 30, 2020
Last update
Jul 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04476394
Responsible party
Sponsor
First posted
Jul 20, 2020
Start date
Aug 3, 2020 (estimated)
Primary completion
Sep 30, 2020 (estimated)
Completion
Sep 30, 2020 (estimated)
Last update
Jul 20, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion